VIGL

Vigil Neuroscience (VIGL)

Vigil Neuroscience Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:VIGL

1 2 3 4 5 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/08	20 : 40	GlobeNewswire Inc.	Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/05/08	06 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/05/08	06 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/05/08	06 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/05/08	06 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/05/08	05 : 35	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/05/08	05 : 20	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/05/08	05 : 05	GlobeNewswire Inc.	Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/04/18	05 : 05	GlobeNewswire Inc.	Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/03/26	20 : 05	GlobeNewswire Inc.	Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/03/20	20 : 05	GlobeNewswire Inc.	Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/03/13	20 : 05	GlobeNewswire Inc.	Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/03/12	20 : 05	GlobeNewswire Inc.	Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/03/07	06 : 25	GlobeNewswire Inc.	Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/03/02	08 : 08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/03/02	07 : 50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/03/01	06 : 05	GlobeNewswire Inc.	Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/02/15	01 : 33	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/02/08	06 : 05	GlobeNewswire Inc.	Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/01/12	00 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/01/04	06 : 30	GlobeNewswire Inc.	Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones	NASDAQ:VIGL	Vigil Neuroscience Inc
2023/11/23	06 : 05	GlobeNewswire Inc.	Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference	NASDAQ:VIGL	Vigil Neuroscience Inc
2023/11/17	06 : 31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VIGL	Vigil Neuroscience Inc
2023/11/17	06 : 05	GlobeNewswire Inc.	Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE	NASDAQ:VIGL	Vigil Neuroscience Inc
2023/11/07	21 : 30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:VIGL	Vigil Neuroscience Inc
2023/11/07	21 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VIGL	Vigil Neuroscience Inc
2023/11/07	21 : 05	GlobeNewswire Inc.	Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update	NASDAQ:VIGL	Vigil Neuroscience Inc
2023/10/17	20 : 05	GlobeNewswire Inc.	Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease	NASDAQ:VIGL	Vigil Neuroscience Inc
2023/10/13	05 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VIGL	Vigil Neuroscience Inc
2023/10/06	05 : 01	GlobeNewswire Inc.	Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit	NASDAQ:VIGL	Vigil Neuroscience Inc